Keywords
Alimentary Canal
Barium Swallows
Colorectal Cancer
Digestive Oncology
Endocrine Disorders
Endoscopy
Authors:
Laria Santo De Sousa
State University of Bahia, Brazil
Correspondence to Author: Laria Santo De Sousa
Abstract:
Background: The best management of HBsAg-negative, anti-HBc-positive patients United Nations agency receive immunological disorder remains unclarified. we tend to consistently reviewed the offered knowledge on potential predictors of the danger of hepatitis B virus (HBV) reactivation in such patients. Methods: A literature search known fifty five studies with 3640 HBsAg-negative, anti-HBc-positive patients United Nations agency received immunological disorder regimens. Results: HBV reactivation was reportable in 236 (6.5%) patients. The pooled HBV reactivation rates failed to dissent between patients with detectable or undetectable HBV desoxyribonucleic acid in studies with hematologic diseases or regimens containing rituximab, however it had been higher in patients with detectable than in those with undetectable HBV desoxyribonucleic acid United Nations agency were taking rituximab-free regimens (14% vs. 2.6%; risk quantitative relation [RR] twelve.67, ninety fifth CI: 95%CI a pair of.39-67.04, P=0.003) or had non-hematological diseases, though the latter wasn’t confirmed by sensitivity analysis (RR eight.80, 95%CI 0.71-109.00, P=0.09). The pooled HBV reactivation rates were lower in patients with positive than in those with negative anti-HBs in studies with hematologic (7.1% vs. 21.8%; RR 0.29, 95%CI 0.19-0.46, P.
Keywords:
Chronic hepatitis B infection, antiviral therapy, lamivudine, entecavir, tenofovir.
Citation:
Laria Santo de Sousa. A systematic analysis of hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive patients on immunosuppressive therapy. Japanese Journal of Gastroenterology 2022.
Journal Info
- Journal Name: Japanese Journal of Gastroenterology
- Impact Factor: 2.709**
- ISSN: 2832-4870
- DOI: 10.52338/jjogastro
- Short Name: JJOGASTRO
- Acceptance rate: 55%
- Volume: 4 (2024)
- Submission to acceptance: 25 days
- Acceptance to publication: 10 days
INDEXING
OUR PUBLICATION BENEFITS
- International Reach
- Peer Review
- Rapid Publication
- Open Access
- High Visibility